enGene Therapeutics Inc.
ENGNW- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001980845
In the last 90 days, enGene Therapeutics Inc. insiders filed 1 open-market purchase and 0 sales; 11 institutions reported holding it in 13F filings for Q2 2026, worth $1.54M in total; no superinvestor holds it.
Other share classesENGN
Q3 2025 vs. Q2 2025
How the institutions holding enGene Therapeutics Inc. changed between Q2 2025 and Q3 2025.
All holders in Q3 2025All holders in Q2 2025
| Measure | Q2 2025 | Of which not filed for Q3 2025 | Q3 2025 | Change |
|---|---|---|---|---|
| Holders | 15 | 1 | 17 | +3 |
| Shares | 4.76M | 300 | 4.58M | −182.4K (−3.8%) |
| Value | $3.70M | $246 | $3.29M | −$410.7K (−11.1%) |
1 institution that held it in Q2 2025 haven't filed for Q3 2025 yet. Not filing isn't selling, so the changes leave them out.
New holders (3)
Institutions that held enGene Therapeutics Inc. at the end of Q3 2025 but not at the end of Q2 2025.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Wolverine Asset Management LLC | 59,431 | $42.2K | 0.00% |
| Caption Management, LLC | 7,144 | $5.07K | 0.00% |
| Clear Street Group Inc. | 300 | $213 | 0.00% |
Sold out (0)
Institutions that held enGene Therapeutics Inc. at the end of Q2 2025 and filed for Q3 2025 without it.
None.
Not filed for Q3 2025 yet (1)
Institutions that held enGene Therapeutics Inc. at the end of Q2 2025 and haven't filed a 13F for Q3 2025. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q2 2025 | Value, Q2 2025 |
|---|---|---|
| Clear Street LLC | 300 | $246 |